Medline: 7989926

The abstract Journal of Clinical Oncology 12(12): 2527-2534, 1994. is available online.

The fulltext Journal of Clinical Oncology 12(12): 2527-2534, 1994. may be available online for subscribers.

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy and autologous stem-cell transplantation for lymphoid malignancies.

Darrington DL, Vose JM, Anderson JR, et al.


To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS).

Patients and Methods:
Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken.

Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL.

There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age > or = 40 years at the time of transplant and who received TBI are at greatest risk.

This is a service of:

Uni Logo

Rheinische Friedrich- Wilhelms- Universität Bonn
Medical Center

Dr. G. Quade